1-N',3-N'-di(ethanethioyl)-1-N',3-N'-dimethylpropanedihydrazide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-N',3-N'-di(ethanethioyl)-1-N',3-N'-dimethylpropanedihydrazide
• 化学式: C₉H₁₆N₄O₂S₂
• 分子量: 276.4
• InChiKey: YKSZFBKDTWUVIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Synthesis of taxol enhancers
  申请人：Chen Shoujun

  公开号：US20090005594A1

  公开（公告）日：2009-01-01

  Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R 1 and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R 2 is an aryl group or a substituted aryl group, then R 5 is a hydrazine protecting group; and when R 2 is an aliphatic or substituted aliphatic group, then R 5 is —H or a hydrazine protecting group. R 10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

  本发明公开了一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。该酰肼起始化合物由结构式（I）表示：硫代酰肼产物化合物由结构式（II）表示：在结构式（I）-（II）中，R1和R2分别独立地表示脂肪基，取代脂肪基，芳基或取代芳基，或者R1和R2连同它们所连接的碳和氮原子形成一个非芳杂环环，可选地融合到一个芳环上。当R2为芳基或取代芳基时，R5是一个肼保护基；当R2为脂肪基或取代脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。该方法包括将起始化合物与硫酰化试剂反应的步骤。
• Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP2100605A1

  公开（公告）日：2009-09-16

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Z and R1 to R6 have meanings given in the description, for use in the treatment of melanoma or renal cancer by administration of said compound, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog. There is also provided the use of a compound of formula (I) for the production of a medicament for administration, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog, for treating melanoma or renal cancer.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐，其中 Y、Z 和 R1 至 R6 具有描述中给出的含义，用于通过在相同或单独的药物组合物中与紫杉醇或紫杉醇类似物一起施用所述化合物来治疗黑色素瘤或肾癌。还提供了式(I)化合物用于生产治疗黑色素瘤或肾癌的药物，在相同或单独的药物组合物中，与紫杉醇或紫杉醇类似物一起给药。
• TAXOL ENHANCER COMPOUNDS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1406870B1

  公开（公告）日：2009-11-11
• Paclitaxel enhancer compound
  申请人：Koya Keizo

  公开号：US20080242702A1

  公开（公告）日：2008-10-02

  One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R 7 R 8 )—. R 1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R 2 -R 4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently —H, an aliphatic or substituted aliphatic group, or R 7 is —H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.
• US7368473B2
  申请人：——

  公开号：US7368473B2

  公开（公告）日：2008-05-06